PDS Biotechnology Receives Nasdaq Deficiency Notice for Minimum Bid Price
PDSB is trading near its 52-week low of $0.601 (13% above the low) on light trading volume (0.2× avg).
Summary
PDS Biotechnology Corp has received a Nasdaq deficiency notice on February 25, 2026, for failing to meet the minimum $1.00 bid price requirement. The company's stock currently trades at $0.6821, triggering the non-compliance. PDS Biotechnology now has 180 days, until August 24, 2026, to regain compliance, with a potential for an additional 180-day extension. This is a material event for the small-cap biotech firm, as failure to resolve the issue could lead to delisting from the Nasdaq Capital Market, significantly impacting its visibility and access to capital. Investors should closely watch for the company's strategy to regain compliance, which may include a reverse stock split.
At the time of this announcement, PDSB was trading at $0.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $37.3M. The 52-week trading range was $0.60 to $1.92. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.